Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation (NASDAQ: RGEN) is a global life sciences company specializing in the development, production, and commercialization of innovative bioprocessing technologies and systems that enhance the efficiency of biological drug manufacturing. Headquartered in Waltham, Massachusetts, the company operates additional manufacturing facilities in Sweden, Estonia, France, Germany, Ireland, the Netherlands, and the United States.
Repligen is renowned for its high-quality bioprocessing products, which are essential in the production of biological drugs. The company's product portfolio includes Protein A, a critical reagent used in the manufacturing of monoclonal antibody-based therapeutics, and several growth factor products that boost cell culture productivity in biomanufacturing. Additionally, Repligen offers OPUS™ (Open Platform User Specified) single-use chromatography columns, which are pivotal in the biologics purification process.
The company serves a diverse customer base that includes major life sciences and biopharmaceutical companies, as well as contract development and manufacturing organizations (CDMOs) worldwide. Repligen markets its products globally through a direct sales organization in the U.S., Europe, and Asia, complemented by strategic partnerships in select regions. North America remains the primary market, contributing the majority of the company's revenue.
Recent achievements include the acquisition of Metenova AB, a leading innovator in magnetic mixing technologies, to expand its Fluid Management portfolio. Despite challenges in the bioprocessing market, Repligen continues to exhibit resilience with steady revenue growth, particularly in its Analytics and Chromatography franchises.
Financially, Repligen reported second quarter revenues of $159.2 million in 2023 and has adjusted its full-year revenue guidance to a range of $635-$665 million. The company remains optimistic about overcoming current market headwinds, with a growing pipeline of opportunities expected to bolster orders in the fourth quarter.
Overall, Repligen's commitment to bioprocessing technology leadership and continuous innovation positions it as a significant player in the life sciences industry, driving advancements that support the development of life-saving biological drugs.
Repligen Corporation (NASDAQ:RGEN) announced its participation in the 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. CEO Tony J. Hunt will present on January 13 at 9:10 a.m. EST. A live webcast of the presentation will be available on the Company’s investor relations website and will be accessible for replay afterward.
The company, based in Waltham, Massachusetts, focuses on bioprocessing technologies aimed at improving the efficiency of manufacturing biological drugs, serving biopharmaceutical developers and CDMOs globally.
Repligen Corporation (NASDAQ: RGEN) successfully closed its underwritten public offering of 1.725 million shares at $181 each, generating gross proceeds of approximately $312.2 million. After deducting fees, the net proceeds are expected to be about $298 million, intended for working capital and general corporate purposes, including potential investments in complementary businesses. The offering included full exercise of the underwriters’ option for an additional 225,000 shares. The company has no current agreements for acquisitions.
EC Mergers & Acquisitions has announced the successful sale of ARTeSYN BioSolutions to Repligen Corporation for a total transaction value of $200M. This includes $130M in cash and $70M in Repligen common stock. ARTeSYN specializes in single-use solutions for bioprocessing, anticipating $30M in pro forma revenue for 2020. The acquisition is expected to generate approximately $33M-$36M in revenue for Repligen in 2021, enhancing its portfolio in bioprocessing technologies.
Repligen Corporation (NASDAQ: RGEN) has priced a public offering of 1.5 million shares at $181 each, aiming to raise approximately $271.5 million before expenses. The underwriters hold a 30-day option for an additional 225,000 shares. Proceeds will be used for working capital and general corporate purposes, including potential acquisitions and investments. The offering is scheduled to close around December 10, 2020, pending customary conditions. J.P. Morgan and Stifel are the lead managers of the offering.
Repligen Corporation (NASDAQ: RGEN) has commenced a public offering of 1.5 million shares of its common stock, with a potential additional 225,000 shares available for underwriters. Proceeds will be used for working capital and to explore acquisitions, though no current agreements exist. The offering is subject to market conditions, and completion timing is uncertain. J.P. Morgan and Stifel are managing the offering, which will follow a previously filed shelf registration statement with the SEC.
Repligen Corporation (NASDAQ:RGEN) reported record quarterly revenue of $94.1 million, marking a 35% year-over-year growth with 31% organic growth. The company raised its full-year revenue guidance to $348-$352 million, implying a 29%-30% total revenue growth. COVID-related revenues contributed approximately 14% to quarterly revenue and 55% to growth. Repligen also completed the acquisition of Non-Metallic Solutions and plans to acquire ARTeSYN Biosolutions, enhancing its systems strategy.
Repligen Corporation (NASDAQ:RGEN) announced a definitive agreement to acquire ARTeSYN Biosolutions for approximately $200 million, enhancing its portfolio of single-use downstream bioprocessing systems. The acquisition is expected to generate around $30 million in pro forma revenue for ARTeSYN in 2020 and contribute $33 to $36 million in 2021, with breakeven adjusted earnings per share in the same year and accretive results anticipated in 2022. This move complements previous acquisitions of Engineered Molding Technologies and Non-Metallic Solutions, positioning Repligen as a leading player in the bioprocessing market.
Repligen Corporation (NASDAQ:RGEN) will announce its third quarter 2020 financial results on November 5, 2020, before the market opens. A conference call will take place at 8:30 a.m. EST to discuss the results and business updates. Investors can access the call by phone or via a webcast on the company’s Investor Relations page. Repligen is a global life sciences company focused on developing bioprocessing technologies that enhance the manufacturing of biological drugs.
Repligen Corporation (NASDAQ:RGEN) reported record quarterly revenue of $87.5 million, a year-over-year increase of 24% with 19% organic growth. The company raised its fiscal year revenue guidance to $332-$340 million, reflecting anticipated margins expansion and continued demand amid COVID-19 vaccine programs. Gross margin improved to 57.9%, with EPS rising to $0.30 from $0.17 a year ago. The acquisition of Engineered Molding Technology supports RGEN's strategic focus on expanding its single-use portfolio.
On June 15, 2020, Repligen Corporation (NASDAQ:RGEN) announced the appointment of Carrie Eglinton Manner to its Board of Directors. With over 23 years in the healthcare sector, she brings extensive leadership experience, notably as Senior VP at Quest Diagnostics and former President & CEO at GE Healthcare. Her expertise in business growth and profitability is expected to support Repligen's innovation-based strategy. The Board expressed confidence in her ability to enhance company operations and expand its market presence in bioprocessing technologies.
FAQ
What is the current stock price of Repligen (RGEN)?
What is the market cap of Repligen (RGEN)?
What does Repligen Corporation specialize in?
Where is Repligen's headquarters located?
What are some key products offered by Repligen?
Who are Repligen's primary customers?
How does Repligen market its products?
What recent acquisition has Repligen made?
What was Repligen's revenue for the second quarter of 2023?
What is Repligen's revenue guidance for the year 2023?
Which regions contribute the most to Repligen's revenue?
What is Repligen's focus area?
